Phase 3 N=250 Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial
SARS-CoV-2
Primary: Number of Participants With COVID 19 Severity — 5; 4; 2; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=182 ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
Clostridium Difficile Infection
Primary: Recurrence of CDI up to 8 Weeks — 11; 37 Participants — p=<0.001
Phase 3 N=58 Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients
Scoliosis · Pain
Primary: Post-operative Opioid Consumption (mg/kg) — 0.267; 0.340 mg/kg — p=<0.05
Phase 3 N=839 Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
Pneumococcal Disease
Primary: Percentage of Participants Reporting Prompted Local Reactions Within 7 Days After Vaccination — 37.7; 39.1; 37.2; 15.1 Percentage of participants
Phase 3 N=13 Progesterone Effect on Individuals Diagnoses With AD and PTSD.
Alcohol Dependence · Post-Traumatic Stress Disorder (PTSD)
Primary: Visual Analogue Scale of Craving (VASC) Baseline no Script — 1.29; 0.60 units on a scale
Phase 3 N=2,539 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
Overweight · Obesity
Primary: Percent Change From Baseline in Body Weight (Primary Treatment Period) — -2.4; -16.0; -21.4; -22.5 percent change — p=<0.001
Phase 3 N=415 MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
Glabellar Lines · Lateral Canthal Lines
Primary: The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) — 0; 78; 66 Participants
Phase 3 N=70 Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
Moderate to Severe Asthma
Primary: Post-vaccination Strain-specific Hemagglutination Inhibition (HAI) Antibody Geometric Mean Fold Rises (GMFRs) — 7.34; 4.75; 1.76; 1.46 Fold change
Phase 3 N=82 The Bladder Instillation Comparison Study
Urinary Bladder Neoplasms
Primary: Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03 — 15; 14; 20 Participants
Phase 3 N=1,971 Immune Modulators for Treating COVID-19
Covid19
Primary: Number of Participants Who Had Recovered by Day 28 — 421; 405; 414; 397 Participants — p=0.0793
Phase 3 N=666 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions (LR) Within 7 Days After Dose 1 — 58.2; 51.3; 26.3; 20.0 Percentage of participants
Phase 3 N=1,000 A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
Rabies · Communicable Disease · Virus Diseases
Primary: Rabies Virus Neutralizing Activity (RVNA) of Geometric Mean Concentration (GMC) at Study Day 8 — 4.346; 0.232 IU/mL
Phase 3 N=77 Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
Wilson Disease
Primary: Serum NCC Concentration — 46.5; 58.7 µg/L
Phase 3 N=114 Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage.o
Abortion, Spontaneous · Abortion in First Trimester · Pain Uterus
Primary: Pain With Cervical Dilation — 52; 45 units on a scale
Phase 3 N=793 Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
Prostatic Neoplasms
Primary: Overall Survival (OS) — 15.8; 14.6 Months — p=0.2616